PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Eiger Biopharmaceuticals Inc (EIGR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US28249U1051

CUSIP

15117E107

Sector

Healthcare

IPO Date

Jan 30, 2014

Highlights

Market Cap

$2.55M

EPS (TTM)

-$58.50

Year Range

$1.10 - $8.27

Target Price

$30.00

Short %

3.22%

Short Ratio

3.72

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Eiger Biopharmaceuticals Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


EIGR (Eiger Biopharmaceuticals Inc)
Benchmark (^GSPC)

Returns By Period


EIGR

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of EIGR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20242.30%-18.72%-10.63%-69.56%
202361.02%-1.05%-52.29%14.84%8.74%-37.14%-3.41%27.04%-64.69%-14.43%30.31%-33.99%-80.97%
2022-16.76%-7.41%107.50%-17.23%1.02%-9.22%37.94%-4.95%-8.84%-32.14%-11.15%-74.01%-77.26%
2021-21.81%5.83%-12.98%-4.07%-7.42%8.40%-6.57%2.26%-17.94%0.90%-8.75%-15.61%-57.77%
2020-17.05%-23.22%-28.35%9.41%62.23%-20.46%4.69%11.14%-27.13%9.09%2.93%34.46%-17.52%
201937.60%-5.58%5.91%-21.82%0.46%-3.46%4.43%-1.54%-5.96%6.34%20.64%13.31%46.65%
2018-37.99%6.94%6.49%-10.66%61.93%-14.39%-17.21%27.72%-6.98%-0.17%-11.44%-4.24%-27.17%
20174.72%-7.38%1.33%-31.00%-15.82%18.80%10.13%6.32%18.92%1.36%4.48%19.74%19.74%
2016-23.81%-16.96%20.22%23.08%2.28%-6.11%-1.87%-23.29%-10.25%-14.49%7.42%-5.28%-47.17%
2015-12.80%6.58%4.35%-85.69%-14.76%-45.45%-4.76%-6.67%-6.25%6.67%58.93%-17.42%-92.47%
20143.55%33.41%5.49%-1.43%-24.00%79.40%-22.91%-6.64%-9.28%5.64%11.13%59.04%138.75%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of EIGR is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of EIGR is 88
Overall Rank
The Sharpe Ratio Rank of EIGR is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of EIGR is 99
Sortino Ratio Rank
The Omega Ratio Rank of EIGR is 99
Omega Ratio Rank
The Calmar Ratio Rank of EIGR is 22
Calmar Ratio Rank
The Martin Ratio Rank of EIGR is 55
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Eiger Biopharmaceuticals Inc (EIGR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
EIGR
^GSPC

There is not enough data available to calculate the Sharpe ratio for Eiger Biopharmaceuticals Inc. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
EIGR (Eiger Biopharmaceuticals Inc)
Benchmark (^GSPC)

Dividends

Dividend History


Eiger Biopharmaceuticals Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


EIGR (Eiger Biopharmaceuticals Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Eiger Biopharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Eiger Biopharmaceuticals Inc was 99.99%, occurring on Apr 2, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Mar 20, 20152274Apr 2, 2024
-50.13%Mar 17, 201455Jun 3, 201419Jun 30, 201474
-42.4%Jul 7, 201471Oct 14, 201440Dec 10, 2014111
-23.64%Dec 30, 201425Feb 4, 201520Mar 5, 201545
-13.56%Feb 28, 20142Mar 3, 20147Mar 12, 20149

Volatility

Volatility Chart

The current Eiger Biopharmaceuticals Inc volatility is 139.60%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


EIGR (Eiger Biopharmaceuticals Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Eiger Biopharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Eiger Biopharmaceuticals Inc.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab